https://techcrunch.com/2020/01/13/codagenix-raises-20-million-for-a-new-flu-vaccine-and-other-therapies/

2 0

Coadagenix, a company developing vaccines and viral therapies for illnesses ranging from the flu and respiratory viruses to dengue fever has raised $20 million in a new round of financing. The company’s new investment round was led by Adjuvant Capital with additional participation from Euclidean Capital and Topspin Partners . Codagenix will use the funds to support clinical development of its general flu vaccine and the first RSV vaccine for elderly patients — who are more at risk to serious consequences from contracting the virus. The company uses a technology called “codon deoptimization” to make versions of viruses and viral therapies that are rendered relatively harmless by replacing more virulent pathogens with milder strains. Full story

14 January

wait